Loop diuretics enhance the secretion of prostacyclin in vitro, in healthy persons, and in patients with chronic heart failure

European Journal of Clinical Pharmacology

Volumn 55, Issue 2, 1999, Pages 117-124

  Liguori, A ^a   Casini, A ^b   Di Loreto, M ^b   Andreini, I ^b   Napoli, C ^a,c,d  

^a Pellegrini Hospital   (Italy)

^b Menarini Ricerche   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d NONE   (Italy)

Author keywords

Congestive heart failure; Loop diuretics; Prostacyclin

Indexed keywords

DIURESIX; FUROSEMIDE; LOOP DIURETIC AGENT; PROSTACYCLIN DERIVATIVE; TORASEMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; FOLLOW UP; HUMAN; HYDROLYSIS; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN DEGRADATION; RADIOIMMUNOASSAY; STATISTICAL ANALYSIS; VASCULAR SMOOTH MUSCLE; VASODILATATION;

6-KETOPROSTAGLANDIN F1 ALPHA; DIURETICS; ENDOTHELIUM, VASCULAR; EPITHELIUM; EPOPROSTENOL; FEMALE; FUROSEMIDE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; KIDNEY; MALE; MIDDLE AGED; SULFONAMIDES; THROMBOXANE B2; VASODILATOR AGENTS;

EID: 0032967507     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050605     Document Type: Article

References (35)

1. Wilcox CS (1991) Diuretics. In: Brenner BM, Rector FC (eds) The kidney. WB Saunders, Philadelphia, pp 2123-2147
2. Neugebager G, Besenfelder E, van Mollendorf E (1988) Pharmacokinetics and metabolism of torasemide in men. Arzneimittel forschung 38: 164-166
3. Scheen AJ, Van Crombrencq JC, Delarge J, Luyckk AS (1986) Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study. Eur J Clin Pharmacol 31: S35-S42
4. Dikshit K, Vyden JK, Chatterjee K, Prakash R, Swan HJC (1973) Renal and extrarenal effects of furosemide in congestive heart failure after acute myocardial infarction. N Engl J Med 288: 1087-1090
5. Johnston GD, Hiatt WR, Nies AS, Payne NA, Murphy RC, Gerber JG (1983) Factors modifying the early nondiuretic vascular effects of furosemide in man. Circ Res 53: 630-635
6. Gerber JG (1983) Role of prostaglandins in the hemodynamic and tubular effects of furosemide. Fed Proc 42: 1707-1711
7. Lundergon CF, Fitzpatrick TM, Rose JC, Ramwell PW, Kot P (1988) Effect of cyclooxygenase inhibition on the pulmonary vasodilator response to furosemide. J Pharmacol Exp Ther 246: 102-106
8. Kirsten R, Tuber TD, Nelson K, Heintz B, Pooth R (1991) Vasodilatatory prostaglandins and loop diuretics. In: Andreucci VE, Dal Canton A (eds) New therapeutic strategies in nephrology. Kluwer, Norwell, MA, pp 244-246
9. Schlondorff D (1986) Renal prostaglandin synthesis and specific actions of prostaglandins. Am J Med 81 [Suppl 2B]: 1-11
10. Wiemer G, Fink E, Linz W, Hropot M, Scholkens BE, Wohlfart P (1994) Furosemide enhances the release of endothelial kinins, nitric oxide and prostacyclin. J Pharmacol Exp Ther 271: 1611-1615
11. Liguori A, D'Armiento FP, Casini A, Leccese M, Napoli C (1997) Loop diuretics enhanced the secretion of prostacyclin in vitro and in patients with heart failure (abstract). J Am Coll Cardiol 29 [Suppl A]: 152A
12. Brater DC, Chennavasin P, Dehmer GJ (1984) Prolonged hemodynamic effect of furosemide in congestive heart failure. Am Heart J 108: 1031-1035
13. Ciafrè SA, D'Armiento FP, Liguori A, Di Gregorio F, Vecchione R, Gandhi Y, Sorice P, Varriale A, Napoli C, Calì A (1992) Angiotensin II evokes the release of ET-1 from human endothelial cells in vitro. Am J Clin Pathol 98: 379-380
14. Ciafrè SA, D'Armiento FP, Di Gregorio F, Colasanti P, Di Benedetto A, Langella A, Di Ieso N, Liguori A, Colasanti R, Napoli C, Sorice P, Varriale A, Calì A (1993) Relations between angiotensin II and endothelin-1 release in human endothelial cells. Recenti Prog Med 84: 248-253
15. Di Gregorio F, Liguori A, Ciafrè SA, Napoli C (1996) Relations between adrenergic response and atrial natriuretic factor release in patients with mild to moderate heart failure. Exp Clin Cardiol 2: 94-102
16. Wiemer G, Scholkens BA, Linz W (1994) Endothelial protection by converting enzyme inhibitors. Cardiovasc Res 28: 166-172
17. Setaro JF, Zaret B, Schulman DA (1990) Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular performance. Am J Cardiol 66: 981-989
18. Napoli C, Liguori A, Sorice P, Ciafrè SA, Di Ieso N, D'Armiento FP (1996) Relations between vasoactive hormones and diastolic function in hypertensive uraemic patients. J Intern Med 240: 389-394
19. Liguori A, Napoli C, Ciafrè SA, D'Armiento FP, Di Gregorio F, Posca T, Di Ieso N, Di Benedetto A, Colasanti P, Ferrara A, Varriale A, Sorice P (1992) Role of arterial hypertension in plasma secretion of prostacyclin during renal failure in man. Eur J Pharmacol Sci 14: 305-308
20. Alam I, Ohuchi K, Levine L (1979) Determination of cyclooxygenase products and prostaglandin metabolites using high pressure liquid chromatography and radioimmunoassay. Anal Biochem 93: 339-345
21. Corso G, Colavita C, Esposito M, Roma R, Napoli C, Zamparelli M, Ansanelli V (1995) Gas chromatography-mass spectrometry analysis of fatty acids in human milk from forty perperae living in Southern Italy. Eur J Pharmacol Sci 17: 215-219
22. Schrerer B, Weber PC (1979) Time-dependent changes in prostaglandin excretion in response to furosemide in man. Clin Sci 56: 77-81
23. MacKay IG, Muir AL, Watson ML (1984) Contribution of prostaglandins to the systemic and renal vascular response to furosemide in normal man. Br J Clin Pharmacol 17: 513-519
24. Van Meyel JJM, Smits P, Russel FGM, Gerlag PGG, Tan Y, Gribnau FWJ (1992) Diuretic efficiency of furosemide during continuous administration versus bolus injection in healthy volunteers. Clin Pharmacol Ther 51: 440-444
25. Thiemermann C (1991) Biosynthesis and interaction of endothelium-derived vasoactive mediators. Eicosanoids 4: 187-202
26. Picckers P, Dormans TP, Russel FG, Hughes AD, Thien T, Schaper N, Smits P (1997) Direct vascular effects of furosemide in humans. Circulation 96: 1847-1852
27. Almirall JJ, Dolman CS, Eidelman DH (1997) Furosemide-induced bronchodilation in the rat bronchus: evidence of a role for prostaglandins. Lung 175: 155-163
28. Kribben A, Fritschka E, Sibold M (1988) Different effects of furosemide on alpha-adreno-receptors and on platelet aggregation in man. Klin Wochenschr 66: 624-627
29. Kaplan MR, Mount DB, Delpire E, Gamba G, Hebert SC (1996) Molecular mechanisms of Na-Cl cotransport. Ann Rev Physiol 58: 649-668
30. Payne JA, Forbush B 3rd (1994) Alternative spliced isoforms of the putative renal Na-K-Cl cotransporter are differentially distributed within the rabbit kidney. Proc Natl Acad Sci USA 91: 4544-4548
31. Payne JA, Xu JC, Haas M, Lytle CY, Ward D, Forbush B 3rd (1995) Primary structure, functional expression, and chromosomal localization of the bumetanide-sensitive Na-K-Cl co-transporter in human colon. J Biol Chem 270: 17977-17985
32. Greenberg S, McGowan C, Xie J, Summer WR (1994) Selective pulmonary and venous smooth muscle relaxation by furosemide. J Pharmacol Exp Ther 270: 1077-1085
33. Melki TS, Foegh ML, Ramwell PW (1986) Implication of thromboxane in furosemide diuresis in rats. Clin Sci 71: 647-650
34. Wilson TW, Badahman AH, Kaushal RD (1993) Thromboxane synthase inhibition enhances furosemide-induced renal vasodilation. Clin Invest Med 16: 372-378
35. Uchida T, Kido H, Yamanaga K, Okita M, Watanabe M (1992) A novel loop diuretic, torasemide, inhibits thromboxane A2-induced contraction in the isolated canine coronary artery. Prostaglandins Leukot Essent Fatty Acids 45: 121-124